MedTrace Logo

Descriptive Pharmacoepidemiological Study of Patients Treated With Iressa

NCT01448187 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 361

Last updated 2016-07-04

No results posted yet for this study

Summary

The aim of the study is to describe the characteristics of patients treated with Iressa (particularly age, gender, phenotype, histology and stage of disease, line of treatment and previous treatments, smoking history, conditions of initiation of treatment (presence of an EGFR-activating mutation) and to evaluate the impact of treatment on the health of the population concerned in terms of morbidity and mortality (clinical benefit, safety,...) and quality of life

Conditions

Sponsors & Collaborators

Principal Investigators

  • Thierry BOUILLET, Dr · Bobigny

  • Elisabeth BRAMBILLA, Pr · Grenoble

  • Jacques CADRANEL, Pr · Paris

  • Jean-Francois MORERE, Pr · Bobigny

  • Maurice PEROL, Dr · Lyon

  • Virginie RONDEAU, PhD · Bordeaux

Eligibility

Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2015-03-31
Completion
2015-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01448187 on ClinicalTrials.gov